Matt Stadler will become chief executive officer of Marsh Agency on January 1, 2027. He succeeds David Eslick, who transitions to the role of chairman.

Stadler currently serves as president of Marsh Agency. He joined Marsh in 2015 following the acquisition of MHBT Inc and became CEO of the Southwest region in 2023. Based in Dallas, he brings more than 20 years of experience advising middle-market businesses on employee benefits and property/casualty insurance needs.

Leadership Transition

Eslick continues as chairman after leading Marsh Agency’s growth strategy for 17 years. Under his tenure, the firm acquired more than 100 agencies and grew to generate more than $5 billion in revenue. Both Stadler and Eslick will report to Nick Studer, president and CEO of Marsh Risk.

John Stanchina succeeds Stadler as president of Marsh Agency. Stanchina is currently CEO of the Mid-Atlantic region and joined Marsh in 2010 via the acquisition of Thomas Rutherfoord Inc. Guy Morrison, currently president and employee health and benefits practice leader for the Mid-Atlantic region, will succeed Stanchina as CEO of that region. Morrison joined Marsh in 2011 through the acquisition of Strategic Benefit Solutions.

What the Numbers Show

Marsh Agency operates within Marsh (NYSE: MRSH), a global professional services firm with annual revenue of $27 billion and more than 95,000 colleagues. The agency unit itself generated more than $5 billion in revenue under Eslick’s leadership, representing a significant portion of the parent company’s total top line. This concentration highlights the strategic importance of the middle-market segment to Marsh’s broader risk and reinsurance portfolio.

Marsh (NYSE: MRSH) projects that total health benefit costs per employee for US employers will rise 8.2% on average in 2027. This marks the highest annual increase since 2003 and the fifth consecutive year of elevated growth following a decade of more moderate increases.

The preliminary results from Marsh’s 2026 National Survey of Employer-Sponsored Health Plans, based on responses from over 1,800 employers, indicate significant pressure on corporate budgets. Without intervention, employers expect current plan costs to surge by 11%.

Cost Drivers and Market Dynamics

Several factors are pushing medical cost trends above general inflation. Sunit Patel, Marsh’s US Chief Actuary for Health and Benefits, identified continued advances in diagnostics and therapeutics as a primary driver. While these treatments improve outcomes, they often cost more than the therapies they replace. Additionally, health system consolidation and lower government funding for public health programs are driving higher charges within employer plans.

Newer factors have emerged to push cost growth to levels not seen in decades:

• GLP-1 medications: Rising utilization of weight management drugs accounts for a full percentage point of the overall 2027 cost growth. Some employers seeking immediate relief have dropped this coverage.
• AI-enabled billing: Rapid adoption of AI software for claims submission has resulted in more claims being filed, including higher-level claims for reimbursement.
• No Surprises Act: Larger-than-expected payments to out-of-network providers through the Independent Dispute Resolution process are adding to costs.

Employer Response and Employee Impact

The pressure on healthcare budgets is likely to result in higher costs for employees in 2027. The survey found that 59% of employers plan to implement cost-cutting changes to health benefits, such as higher deductibles that increase members’ out-of-pocket expenses.

A separate Marsh survey conducted earlier this year revealed that about two-thirds of large employers (those with 500 or more employees) expect to increase employees’ share of premium costs next year. Consequently, many employees will see paycheck deductions for health coverage rise by more than the overall average cost increase of 8.2%.

Strategic Shifts in Plan Design

While many employers are shifting costs, others are exploring ways to control spending without burdening employees. Over a third of large employers plan to offer non-traditional medical plans in 2027, such as variable copay or high-performance network plans. These options typically feature lower deductibles and charge members less when they select top-performing providers.

Variable copay plans are gaining traction, with 12% of large employers planning to offer them in 2027. Among employers with 20,000 or more employees, this figure rises to 18%.

Guiding members to higher-quality care is becoming a priority. In the National Survey, 58% of large employers indicated that this strategy would be important or very important, up from fifth place in last year’s survey. Managing high-cost claims remains the highest priority, particularly as expensive new therapies for cancer and rare diseases reach the market.

What the Numbers Show

The divergence between the projected 8.2% cost increase and the 11% unchecked cost rise highlights the effectiveness of employer interventions but also underscores the severity of underlying inflation. With GLP-1 drugs alone contributing one full percentage point to the 8.2% total, specialized therapeutic utilization is now a quantifiable, material component of aggregate healthcare inflation, distinct from general medical trend rates.